多索茶碱联合布地奈德对肥胖哮喘患者气道炎症及病情控制水平的影响

Effect of Doxofylline Combined with Budesonide on Airway Inflammation and Disease Control in Obese Asthmatic Patients

目的探究肥胖哮喘患者采用多索茶碱联合布地奈德的治疗方式对气道炎症及病情控制程度的影响。方法方便选取该院于2015年3月-2018年4月收治的肥胖且伴有哮喘的患者50例,以随机分组的方式,分为实验组(n=25,运用多索茶碱联合布地奈德的治疗方案)和对照组(n=25,应用氨茶碱的治疗方案),研究并分析两组患者在治疗前后炎症因子(TNF-α、IL-6)的表达水平、1 s用力呼气容积(FEV1)/用力肺活量(FVC)以及最大呼气流量(PEF)的变化程度。结果两组患者治疗后的炎症因子(TNF-α、IL-6)表达水平较治疗前均有所降低,且实验组中TNF-α=(21.21±4.24)μg/L、IL-6=(18.72±4.13)μg/L均显著低于对照组TNF-α=(29.68±4.45)μg/L、IL-6=(25.32±3.42)μg/L,(t=6.89,P=0.000,t=6.15,P=0.000);而治疗后的FEV1/FVC值以及PEF值较治疗前均有所提高,且实验组FEV1/FVC=(76.68±6.62)%;PEF=(4.95±0.51)L/s显著高于对照组FEV1/FVC=(64.14±5.26)%;PEF=(3.12±0.45)L/s (t=7.42,P=0.000;t=13.45,P=0.000),以上各项数据差异均具有统计学意义(P<0.05)。结论对肥胖哮喘患者采用多索茶碱联合布地奈德的治疗方式可以有效地降低炎症因子(TNF-α、IL-6)的表达水平,同时提高FEV1/FVC值和PEF值。

Objective To investigate the effect of treatment with doxofylline combined with budesonide on airway inflammation and disease control in obese asthma patients.Methods The authors convenient selected 50 patients with obesity and asthma in our hospital from March 2015 to April 2018.They were randomly divided into experimental group (n=25,using doxofylline combined with budesonide treatment plan) and the control group (n=25,treatment with aminophylline),studied and analyzed the expression levels of inflammatory factors (TNF-α,IL-6) in the two groups before and after treatment,1 second forced Gas volume (FEV1)/ forced vital capacity (FVC) and the degree of change in maximum expiratory flow (PEF).Results The expression levels of inflammatory factors (TNF-α,IL-6) in the two groups were lower than those before treatment,and in the experimental group TNF-α=(21.21±4.24)μg/L,IL-6=(18.72±4.13)μg/L,significantly lower than the control group TNF-α=(29.68±4.45)μg/,IL-6=(25.32±3.42)μg/L (t=6.89,P=0.000;t=6.15,P=0.000);and the FEV1/FVC value after treatment and PEF values were higher than before treatment,and the experimental group FEV1/FVC=(76.68±6.62)%;PEF=(4.95±0.51)L/s was significantly higher than the control group FEV1/FVC=(64.14±5.26)%;PEF=(3.12±0.45)L/s (t=67.42,P=0.000;t=13.45,P=0.000),the difference of the above data was statistically significant (P<0.05).Conclusion Treatment of obese asthma patients with doxofylline combined with budesonide can effectively reduce the expression levels of inflammatory factors (TNF-α,IL-6) and increase the FEV1/FVC and PEF values.